

## AUSTRALIAN PRODUCT INFORMATION - DOMION (AGOMELATINE) FILM-COATED TABLETS

### 1 NAME OF THE MEDICINE

Agomelatine.

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 25 mg of agomelatine.

Excipient with known effect: contains sugars as lactose. For the full list of excipients, see *section 6.1 - List of excipients*.

### 3 PHARMACEUTICAL FORM

Orange-yellow, oblong, 9.5 mm long, 5.1 mm wide film-coated tablet with blue imprint of Servier logo on one face.

### 4 CLINICAL PARTICULARS

#### 4.1 THERAPEUTIC INDICATIONS

Treatment in adults of:

- major depressive disorder (MDD) including prevention of relapse
- generalised anxiety disorder (GAD).

#### 4.2 DOSE AND METHOD OF ADMINISTRATION

The recommended daily dose is one 25mg tablet taken orally at bedtime for both MDD and GAD.

If there is no improvement in symptoms the dose may be increased to 50 mg once daily, taken as a single dose of two tablets at bedtime:

- 2 weeks after treatment initiation in patients with MDD
- 4 weeks after treatment initiation in patients with GAD

The maximum recommended dose should not be exceeded.

Dose escalation has been associated with an increased incidence of serum transaminase elevations. Dose increases to 50 mg should only occur following an assessment of the benefits and risk and assessment of liver function.

Liver function tests should be performed in all patients before initiation of treatment and before a dose increase to 50 mg. Treatment with DOMION (agomelatine) should not be initiated if serum transaminase levels are > 3 times the upper limit of normal range (see *section 4.3 – Contraindications* and *section 4.4 - Special warnings and precautions for use*).

During treatment transaminases should be monitored periodically after around 3, 6 (end of acute phase), 12, and 24 (end of maintenance phase) weeks with regimen to be repeated following dose increase to 50 mg and thereafter when clinically indicated (see *section 4.4 - Special warnings and precautions for use*).

Treatment should be discontinued if serum transaminase levels are > 3 times the upper limit of the normal range (see *section 4.3 – Contraindications* and *section 4.4 - Special warnings and precautions for use*).

### Treatment duration

Both MDD and GAD are diseases with a chronic course and long-term treatments are therefore warranted to consolidate response and prevent relapse.

Patients with MDD and/or GAD should be treated for a period of at least six months following response to ensure that they are free of symptoms.

DOMION (agomelatine) tablets may be taken with or without food.

### Switching to agomelatine from other antidepressants (SSRIs) or SNRIs

Patients may experience discontinuation symptoms after cessation from an SSRI/SNRI antidepressant. The product information of the actual SSRI/SNRI should be consulted on how to withdraw the treatment to avoid discontinuation symptoms. DOMION (agomelatine) can be started immediately while tapering the dosage of an SSRI/SNRI (see *section 4.3 – Contraindications* and *section 5.1 - Pharmacodynamic properties*).

### Children and adolescents

Safety and efficacy have not been established in this age group. DOMION (agomelatine) is not recommended for use in children and adolescents aged < 18 years (see *section 4.4 - Special warnings and precautions for use*).

### Elderly Patients

The efficacy and safety of agomelatine (25 to 50 mg/day) have been established in elderly patients with MDD (aged < 75 years). No adjustment in the usual dose is recommended for elderly patients with MDD (aged < 75 years) solely because of their age. As efficacy has not been established in very elderly patients with MDD aged ≥ 75 years DOMION (agomelatine) should not be used in this patient group (see *section 4.4 - Special warnings and precautions for use*).

As data on the use of agomelatine (25 to 50mg/day) in elderly patients with GAD are limited, DOMION is not recommended to treat generalised anxiety disorder in the elderly aged > 65 years (see *sections: 4.4 - Special warnings and precautions for use, 5.1 - Pharmacodynamic properties and 5.2 – Pharmacokinetic properties*).

DOMION (agomelatine) should not be used for the treatment of MDD or GAD in elderly patients with dementia since the safety and efficacy of DOMION (agomelatine) have not been established in these patients

### Patients with renal impairment

No relevant modification in agomelatine pharmacokinetic parameters in patients with severe renal impairment has been observed. However, as only limited clinical data on the use of agomelatine in patients with moderate or severe renal impairment are available, caution should be exercised when prescribing DOMION (agomelatine) to these patients.

### Patients with hepatic impairment

DOMION (agomelatine) is contraindicated in patients with hepatic impairment (see *section 4.3 - Contraindications*).

### Treatment discontinuation

No dose tapering is needed on treatment discontinuation, as DOMION (agomelatine) does not induce discontinuation symptoms after abrupt treatment cessation.

## 4.3 CONTRAINDICATIONS

DOMION (agomelatine) is contraindicated in patients:

- with a history of previous hypersensitivity to the active ingredient or any of the excipients listed in *section 6.1 - List of excipients*.
- with hepatic impairment (i.e. cirrhosis or active liver disease) or transaminases exceeding 3 times the upper limit of normal (see *section 4.2 - Dose and method of administration* and *section –4.4 Special warnings and precautions for use*).
- taking potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin).

## 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

### Monitoring of liver function

***Caution should be exercised before initiation of treatment and close surveillance should be performed during continuing treatment, especially during combined use with medicines associated with risk of hepatic injury or where risk factors for hepatic injury are present.***

In post-marketing experience cases of liver injury, including elevations of liver enzymes (> 10 times upper limit of the normal range), hepatic failure, hepatitis and jaundice have been reported in patients treated with agomelatine, most often during the first months of treatment (see *section 4.8 - Adverse effects (Undesirable effects)*).

Isolated cases of transplantation or death in patients with hepatic failure have been reported following the use of agomelatine. Some patients had hepatic risk factors. This highlights the importance of performing liver function tests in all patients.

The pattern of liver damage is predominantly hepatocellular with serum transaminases usually returning to normal levels following discontinuation of agomelatine. In clinical trials, elevations of serum transaminases (> 3 times the upper limit of the normal range) have been observed in patients treated with agomelatine more commonly on a 50 mg dose.

### Before initiation of treatment:

Treatment with agomelatine should only be initiated after careful consideration of the benefits and risk in patients with hepatic injury risk factors e.g.:

- overweight, obesity, non-alcoholic fatty liver disease, diabetes or use with medicines associated with risk of hepatic injury
- alcohol use disorder and /or substantial alcohol intake.

Baseline liver function tests should be performed in all patients before initiation of treatment. Treatment with agomelatine should not be initiated if serum transaminase levels are > 3 times the upper limit of the normal range (see *section 4.3 - Contraindications*). Caution should be exercised when agomelatine is administered to patients with pre-treatment elevated transaminases (i.e. between the upper limit of the normal ranges and up to ≤ 3 times the upper limit of the normal range).

Frequency of liver function tests:

Before starting treatment and then:

- around 3 weeks
- around 6 weeks (end of acute phase)
- around 12 weeks
- around 24 weeks (end of maintenance phase)
- thereafter when clinically indicated.

When increasing the dosage, liver function tests should again be performed at the same frequency as when starting treatment. Patients who develop any increased serum transaminases should have their liver function tests repeated within 48 hours.

During treatment:

Therapy should be discontinued immediately if any of the following are observed:

- an increase in serum transaminases > 3 times the upper limit of normal (see *section 4.3 - Contraindications*)
- signs or symptoms of potential liver injury (such as dark urine, light coloured stools, yellow skin/eyes, pain in the upper right abdomen, sustained new-onset and unexplained fatigue).

Liver function tests should continue to be performed regularly following discontinuation of therapy until serum transaminases return to normal.

**Suicide Ideation / Suicidality**

In clinical trials, agomelatine is not associated with an increased risk of suicide ideation / suicidality.

The risk of suicide attempt is inherent in patients with depression and may persist until significant remission occurs. This risk must be considered in all patients with depression.

Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases. Patients with a history of suicide-related events or those exhibiting suicidality prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts and should be monitored during treatment.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient's presenting symptoms. Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition and/or the emergence of suicidal ideation/ behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. Patients with comorbid depression associated with other psychiatric disorders being treated with antidepressants should be similarly observed for clinical worsening and suicidality.

Pooled analyses of 24 short-term (4 to 16 weeks), placebo controlled trials of nine antidepressant medicines (SSRIs and others) in 4,400 children and adolescents with MDD (16 trials), obsessive compulsive

disorder (four trials) or other psychiatric disorders (four trials) have revealed a greater risk of adverse events representing suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients treated with an antidepressant was 4 % compared with 2 % of patients given placebo. There was considerable variation in risk among the antidepressants, but there was a tendency towards an increase for almost all antidepressants studied. The risk of suicidality was most consistently observed in the MDD trials, but there were signals of risk arising from trials in other psychiatric indications (obsessive compulsive disorder and social anxiety disorder) as well. No suicides occurred in these trials. It is unknown whether the suicidality risk in children and adolescent patients extends to use beyond several months. The nine antidepressant medications in the pooled analyses included five SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) and four non-SSRIs (bupropion, mirtazapine, nefazodone, venlafaxine).

A further pooled analysis of short-term placebo controlled trials of antidepressant medicines (SSRIs and others) showed the increased risk of suicidality during the initial treatment period (generally the first one to two months) extends to young adults (aged 18-24 years) with MDD and other psychiatric disorders. These trials did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 years and older.

Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania have been reported in adults, adolescents and children being treated with antidepressants for MDD as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either worsening of depression and/or emergence of suicidal impulses has not been established, there is concern that such symptoms may be precursors of emerging suicidality.

Families and caregivers of children and adolescents being treated with antidepressants for MDD or for any other condition (psychiatric or non-psychiatric) should be informed about the need to monitor these patients for the emergence of agitation, irritability, unusual changes in behaviour and other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. It is particularly important that monitoring be undertaken during the initial few months of antidepressant treatment or at times of dose increase or decrease.

When treatment duration was considered the incidence of suicidal events was 0.28 per 100 patient-months for agomelatine compared with 0.50 per 100 patient-months for placebo.

### **Bipolar disorder / Mania / Hypomania**

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk of bipolar disorder. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder and depression.

As with other antidepressants, agomelatine should be used with caution in patients with history of bipolar disorder, mania or hypomania and should be discontinued if a patient develops manic symptoms.

### **Lactose intolerance**

DOMION (agomelatine) tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

### **Alcohol**

As with all antidepressants, patients should be advised to avoid alcohol consumption.

### **Combination with CYP1A2 inhibitors (see section 4.3 – Contraindications, section 4.5 - Interactions with other medicines and other forms of interactions and section 5.1 - Pharmacodynamic properties)**

Use caution when combining agomelatine with moderate CYP1A2 inhibitors (e.g. propranolol) as these medicines may result in increased exposure to agomelatine.

### **Electroconvulsive therapy (ECT)**

There is no experience with the combined use of agomelatine and ECT. In animals agomelatine has no proconvulsant properties. Therefore, adverse consequences of combined ECT and agomelatine treatment are considered to be unlikely.

### **Abuse potential**

Agomelatine has no abuse potential. This was assessed in healthy volunteer trials on a specific visual analogue scale or the Addiction Research Centre Inventory 49 (ARCI) checklist.

### **Use in hepatic impairment**

DOMION (agomelatine) is contraindicated in patients with hepatic impairment (see section 4.3 - Contraindications).

### **Use in renal impairment**

As only limited clinical data on the use of agomelatine in patients with moderate or severe renal impairment are available, caution should be exercised when prescribing DOMION (agomelatine) to these patients

### **Use in the elderly**

No adjustment in the usual dose is recommended for elderly patients solely because of their age.

The efficacy and safety of agomelatine (25 to 50 mg/day) have been established in elderly patients with MDD (aged < 75 years). As efficacy has not been demonstrated in elderly patients aged ≥ 75 years, agomelatine should not be used in this patient group (see section 4.2 - Dose and method of administration).

Agomelatine should not be used for the treatment of MDD or GAD in elderly patients with dementia since the safety and efficacy of agomelatine have not been established in these patients.

Data on the use of agomelatine in elderly patients with GAD are limited. Therefore, agomelatine is not recommended to treat GAD in the elderly aged ≥ 65 years (see sections: 4.2 - Dose and method of administration and 5.1 - Pharmacodynamic properties).

### Paediatric use

As safety and efficacy have not been established in this age group, the use of agomelatine in children and adolescents (aged < 18 years) is not recommended.

In clinical trials among children and adolescents treated with other antidepressants, suicide-related behaviour (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour, and anger) were more frequently observed compared to those treated with placebo.

### Effects on laboratory tests

No data available

## 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

### Potential interactions affecting DOMION (agomelatine)

DOMION (agomelatine) is metabolised mainly by cytochromes CYP1A2 (90 %) and CYP2C9/19 (10 %). Medicines that interact with these isoenzymes may decrease or increase the bioavailability of DOMION (agomelatine).

Co-administration of DOMION (agomelatine) with potent CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin are contraindicated. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9 inhibitor, has been shown to markedly inhibit the metabolism of DOMION (agomelatine) resulting in a 60-fold (range 12-412) increase in agomelatine exposure.

Combination of DOMION (agomelatine) with estrogens (moderate CYP1A2 inhibitors) results in a several fold increased exposure of DOMION (agomelatine). While there was no specific safety signal in the 800 patients treated in combination with estrogens, caution should be exercised when prescribing DOMION (agomelatine) with other moderate CYP1A2 inhibitors (e.g. propranolol) until more experience has been gained.

Rifampicin an inducer of all three cytochromes involved in the metabolism of agomelatine may decrease the bioavailability of agomelatine.

Fluconazole, a potent CYP2C9 and CYP2C19 inhibitor, has been shown not to affect the pharmacokinetics of DOMION (agomelatine).

Table 1 - Summary of CYP1A2 and CYP2C9/C19 interactions from agomelatine clinical trials

<b>Contraindicated:</b>	<b>Caution recommended:</b>	<b>No interaction:</b>
<b>Potent CYP1A2 inhibitors</b> (e.g. fluvoxamine and ciprofloxacin)	<b>Moderate CYP1A2 inhibitors</b> (e.g. propranolol) <b>CYP1A2/CYP2C9/CYP2C19 inducers</b> (e.g. rifampicin)	<b>Potent CYP2C9/CYP2C19 inhibitors</b> (e.g. fluconazole)

As the decrease in DOMION (agomelatine) exposure in cigarette smokers due to induction of CYP1A2 is not clinically relevant, no dose adjustment is necessary because a patient is a cigarette smoker (see *section 5.2 - Pharmacokinetic properties*).

### **Use with other antidepressants**

DOMION (agomelatine) should not be combined with fluvoxamine as fluvoxamine is a potent inhibitor of the metabolism of DOMION (agomelatine) (see *section 4.3 - Contraindications*). Caution should be taken when administering DOMION (agomelatine) with other antidepressants as the safety and efficacy of DOMION (agomelatine) in combination with other antidepressants has not been studied in randomised clinical trials.

There is no pharmacokinetic or pharmacodynamic interaction between DOMION (agomelatine) and paroxetine.

### **Lithium**

There is no pharmacokinetic or pharmacodynamic interaction between DOMION (agomelatine) and lithium.

### **Benzodiazepines (lorazepam)**

There is no pharmacokinetic or pharmacodynamic interaction between DOMION (agomelatine) and lorazepam.

### **Potential for DOMION (agomelatine) to affect other medicinal products**

DOMION (agomelatine) inhibits neither CYP1A2 *in vivo* nor the other CYP450 *in vitro* and does not induce CYP450 isoenzymes *in vivo*. Therefore, DOMION (agomelatine) will not modify exposure to medicines metabolised by CYP450. In healthy volunteers DOMION (agomelatine) did not modify the kinetics of theophylline, a CYP1A2 substrate.

### **Drugs highly bound to plasma protein**

DOMION (agomelatine) does not modify free concentrations of drugs highly bound to plasma proteins (e.g. zolpidem, diazepam, sertraline, warfarin, estrogen and salicylic acid) or *vice versa*.

## **4.6 FERTILITY, PREGNANCY AND LACTATION**

### **Effects on fertility**

Oral reproductive toxicity trials with agomelatine in rats showed no effect on fertility at plasma exposures of 60-100-fold human exposure at the maximal recommended clinical dose. No effect of agomelatine on juvenile rat behavioural performances, visual and reproductive function were observed. There were mild non dose dependent decreases in body weight and food intake, delayed preputial separation and decreased long bone growth related to the pharmacological properties and some minor (reversible) effects (e.g., decreased prostate weight with atrophy /decreased amount of seminal fluid, decreased weight of testis) on male reproductive tract without any impairment on reproductive performances.

### **Use in pregnancy**

Australian Pregnancy Category: B1.

Animal trials do not indicate direct or indirect harmful effects with respect to pregnancy, embryofoetal development, parturition or postnatal development at systemic exposures (plasma AUC) of 100-fold or greater the human exposure at the maximal recommended clinical dose. Agomelatine and/or its metabolites passes into the placenta and foetuses of pregnant rats. No clinical data on exposed pregnancies are available. As a precautionary measure, it is recommended to avoid the use of agomelatine during pregnancy.

### **Use in lactation**

It is not known whether agomelatine and/or its metabolites are excreted into human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of agomelatine/metabolites in milk. There were no adverse effects on offspring following oral administration of agomelatine to rats from prior to mating until weaning, with systemic exposures (plasma AUC) of 100-fold human exposure at the maximal recommended clinical dose. The effects of agomelatine on the nursing infant have not been established. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from agomelatine therapy following consideration of the relative benefits of breast feeding for the child and of therapy for the woman.

### **4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

No trials on the effects on the ability to drive and use machines have been performed. While clinical pharmacodynamic trials have shown that agomelatine treatment does not impair cognitive or psychomotor function in healthy volunteers, dizziness and somnolence were reported during clinical trials. As with all psychoactive medicines, patients should be cautioned about their ability to drive a car or operate machinery.

### **4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)**

In clinical trials, over 9,200 patients have received agomelatine 25-50 mg for MDD (N=8,084) or for GAD (N=1,170).

In clinical trials dose escalation was associated with an increase in liver function abnormalities. The incidence of ALT and/or AST elevations > 3x ULN according to agomelatine dose in clinical trials was: 0.6 % on agomelatine 1-10 mg (4/679 patients), 1.3 % on agomelatine 25 mg (72/5,581 patients), 2.6 % on agomelatine 50 mg (66/2,577 patients) and 3.5 % on agomelatine 100 mg (2/57 patients), compared to 0.4 % in the placebo group (6/1,629 patients) – see *section 4.4 - Special warnings and precautions for use*. Whilst 1-10 mg and 100 mg doses were included in dose ranging trials, these are not within the approved therapeutic dose range of 25 mg to 50 mg (see *section 4.2 - Dose and method of administration*).

Patients with MDD and/or GAD display a number of symptoms that are associated with the illness itself. It is therefore sometimes difficult to ascertain which symptoms are a result of the illness itself and which are a result of treatment with agomelatine.

Adverse events were usually mild or moderate and occurred within the first two weeks of treatment. The most common adverse events were headache, nausea, nasopharyngitis and dizziness which were also commonly reported in the placebo treatment group. These adverse events were usually transient and did not generally lead to cessation of therapy (see Table 2).

Table2 - Treatment Emergent adverse events reported by at least 1% of patients with MDD and GAD treated with agomelatine 25/50 mg (MDD and GAD pool)

Preferred Term	Agomelatine 25-50mg (N=9,254 PT=45,612.7)	Placebo (N=1,722 PT=5,450.8)
	% <sup>(1)</sup>	% <sup>(1)</sup>
ALL	62.62	52.96
Headache	13.92	13.24
Nausea	7.10	5.75
Nasopharyngitis	6.08	3.72
Dizziness	5.45	3.37
Somnolence	4.82	2.67
Dry mouth	4.27	3.19
Diarrhoea	4.26	2.73
Insomnia	3.75	2.96
Upper respiratory tract infection	3.33	1.16
Fatigue	3.30	2.15
Back pain	3.23	2.03
Influenza	3.03	2.85
Anxiety	2.86	1.57
Constipation	2.56	2.09
Dyspepsia	2.07	1.28
Abdominal pain upper	2.02	1.22
Sedation	1.74	1.05
Bronchitis	1.63	0.87
Sinusitis	1.59	0.58
Vomiting	1.56	1.51
Urinary tract infection	1.37	1.10
Weight increased	1.34	1.16
Arthralgia	1.26	0.58
Gastroenteritis	1.25	1.05
Irritability	1.24	0.52
Depression	1.19	2.61
Abnormal dreams	1.13	0.41
Abdominal pain	1.11	0.75

**Notes:** N: Number of patients; PT: Number of Patient-Months (PT)

(1): (n/N)x100

Table 3 describes adverse reactions reported with DOMION in the clinical program (MDD and GAD indications). The frequency of side effects is defined by the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $\leq 1/10$ ), uncommon ( $\geq 1/1,000$  to  $\leq 1/100$ ), rare ( $\geq 1/10,000$  to  $\leq 1/1,000$ ), very rare ( $\leq 1/10,000$ ), and not known (cannot be estimated from the

**Australian Product Information – DOMION (agomelatine)**

available data) and have not been corrected for placebo. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 3 - Adverse reactions reported with DOMION in the clinical program (MDD and GAD indications).

<b>System organ class</b>	<b>Frequency</b>	<b>Preferred Term</b>
Psychiatric disorders	Common	Anxiety
	Uncommon	Suicidal thoughts or behaviour ( <i>section 4.4 - Special warnings and precautions for use</i> )
Nervous system disorders	Very common	Headache
	Common	Dizziness
		Somnolence
		Insomnia
	Uncommon	Migraine
Paraesthesia		
Eye disorders	Uncommon	Blurred vision
Gastrointestinal Disorders	Common	Nausea
		Diarrhoea
		Constipation
		Abdominal pain
Hepato- biliary disorders	Common	Increased ALT and/or AST (in clinical trials, increases >3 times the upper limit of the normal range for ALT and/or AST were seen in 1.3% of patients on agomelatine 25 mg daily and 2.6 % on agomelatine 50 mg daily vs. 0.4% on placebo).
	Rare	Hepatitis
Skin and subcutaneous tissue disorders	Uncommon	Hyperhidrosis
		Eczema
	Rare	Erythematous rash
Musculoskeletal and connective tissue disorders	Common	Back pain
General disorders and administration site conditions	Common	Fatigue

Table 4 describes adverse reactions reported with DOMION during post-marketing experience (MDD and GAD indications).

Table 4 - Adverse reactions reported during post-marketing experience (MDD and GAD indications)

System organ class	Frequency*	Preferred Term
Psychiatric disorders	Common	Abnormal dreams
	Uncommon	Agitation and related symptoms (such as irritability and restlessness)
		Aggression
		Nightmares
		Mania/hypomania These symptoms may also be due to the underlying disease (see <i>section 4.4 - Special warnings and precautions for use</i> ).
	Rare	Confusional state
Rare	Hallucinations	
Nervous system disorders	Uncommon	Restless leg syndrome
	Rare	Akathisia
Ear and labyrinth disorders	Uncommon	Tinnitus
Gastrointestinal Disorders	Common	Vomiting
Hepato- biliary disorders	Uncommon	Increased gamma-glutamyltransferase (GGT)(>3 times the upper limit of the normal range)
	Rare	Increased alkaline phosphatase (>3 times the upper limit of the normal range)
		Hepatic failure <sup>(1)</sup> (see <i>section 4.4 - Special warnings and precautions for use</i> ).
		Jaundice
Skin and subcutaneous tissue disorders	Uncommon	Pruritus
		Urticaria
	Rare	Face oedema and angioedema
Musculoskeletal and connective tissue disorders	Uncommon	Myalgia
Renal and urinary disorders	Rare	Urinary retention
Investigations	Common	Weight increased
	Uncommon	Weight decreased

**Notes:** \* Frequency estimated from clinical trials for adverse reactions detected from spontaneous reports  
 (1) Few cases were exceptionally reported with fatal outcome or liver transplantation in patients with hepatic risk factors

**Reporting suspected adverse effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

**4.9 OVERDOSE**

**For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).**

There is limited experience with agomelatine overdose. Experience with agomelatine in overdose has indicated that epigastralgia, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis or malaise have been reported. One person having ingested 2,450 mg of agomelatine, recovered spontaneously without cardiovascular and biological abnormalities. No specific antidotes for agomelatine are known. Management of overdose should consist of treatment of clinical symptoms and routine monitoring. Medical follow-up in a specialised environment is recommended.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 PHARMACODYNAMIC PROPERTIES**

#### **Mechanism of action**

Pharmacotherapeutic group: Other antidepressants (ATC-code: NO6AX22)

Agomelatine is a melatonin receptor (MT<sub>1</sub> and MT<sub>2</sub>) agonist and 5-HT<sub>2C</sub> receptor antagonist. Agomelatine has shown antidepressant-like and anxiolytic-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress), in models with circadian rhythm desynchronisation and in models related to stress and anxiety.

*In vitro* studies indicate that agomelatine has no effect on monoamine uptake and no affinity for  $\alpha$  or  $\beta$  adrenergic, histaminergic, cholinergic, dopaminergic, or benzodiazepine receptors. Agomelatine has no influence on the extracellular levels of serotonin and increases dopamine and noradrenaline release specifically in the prefrontal cortex. These properties may explain why, compared with other antidepressants, it has less gastrointestinal (e.g. vomiting, constipation) and sexual function (e.g. libido decrease) side effects, and no cardiovascular side effects in clinical trials.

In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset.

Agomelatine resynchronises circadian rhythms in animal models of circadian rhythm disruption.

In patients with MDD, treatment with agomelatine 25 mg increased slow wave sleep without modification of REM (Rapid Eye Movement) sleep amount or REM latency. Agomelatine 25 mg also induced an advance of the time of sleep onset and of minimum heart rate. From the first week of treatment, onset of sleep and the quality of sleep were significantly improved without daytime clumsiness as assessed by patients.

In patients with GAD, getting off to sleep and quality of sleep were significantly improved with agomelatine compared to placebo from Week 2 as assessed by patients.

At therapeutic doses, in healthy volunteers, agomelatine preserves daytime alertness and memory, with no sedation in the morning following drug intake.

#### Cardiovascular

In clinical trials, agomelatine had no effect on QT interval and no clinically significant effect on heart rate, blood pressure and ECG tracings

#### Withdrawal / Discontinuation

The abrupt discontinuation of agomelatine was evaluated in a specific active control trial (CL3-030) using the Discontinuation Emergent Signs and Symptoms (DESS) checklist. Patients with MDD were treated under

double-blind conditions with agomelatine 25 mg or paroxetine 20 mg over a 12-week period. Only those who remitted at week eight and sustained that remission until week 12 were randomised to placebo or the initial active treatment for a two-week double-blind period. Patients discontinued from agomelatine to placebo were compared to those who continued treatment on agomelatine and, likewise for the active control paroxetine. The abrupt discontinuation of agomelatine was not associated with discontinuation symptoms [ $p=0.250$  for difference between the agomelatine and placebo groups]. The sensitivity of the trial was demonstrated by the presence of significant emergent discontinuation symptoms following the abrupt discontinuation of treatment with the active control paroxetine [ $p<0.001$  for difference between the paroxetine and placebo groups].

In a long-term GAD treatment trial [CL3-050] abrupt cessation of agomelatine was not associated with discontinuation symptoms.

### Sexual function

No deleterious effect on sexual function (SEX-FX total score and SEX-FX sub-scores and items) was observed during agomelatine 50 mg treatment over 12 or 24-week treatment periods in a specific sexual dysfunction comparative trial in remitted depressed patients. There was a numerical trend towards less sexual emergent dysfunction on agomelatine 50 mg than venlafaxine 150 mg for SEX-FX drive arousal or orgasm scores but statistical separation was not achieved.

A separate pooled analysis of trials using the Arizona Sexual Experience Scale (ASEX) showed that agomelatine was not associated with sexual dysfunction. In healthy volunteers agomelatine did not affect sexual function, in contrast to paroxetine.

### **Clinical trials**

#### Acute treatment of Major Depressive Disorder (MDD)

The efficacy and safety of agomelatine in the treatment of major depression have been studied in a clinical development programme including 8,084 patients treated with therapeutic doses of 25 mg or 50 mg. Among over 7,130 patients treated with agomelatine for between six weeks and one year, 2,356 patients were treated with agomelatine for six months and 1,094 patients were treated with agomelatine for one year.

Ten placebo-controlled trials have been performed to investigate the short-term efficacy of agomelatine in MDD in adults, with fixed dose and/or dose up-titration. At the end of treatment (over six or eight weeks), five one step up-titration trials and one of the fixed dose trials showed statistically the superiority of agomelatine over placebo on the primary outcome criterion HAM-D total score and consistent results across secondary criteria (trials CL2-014, CL3-042, CL3-043, CL3-069, CAGO178A2301 for 50 mg dose (but not 25 mg dose), CAGO178A2302 for 25 mg dose (but not 50 mg dose)). Response rates were statistically significantly higher with agomelatine compared with placebo. The response to treatment of MDD was defined as a decrease in HAM-D total score of at least 50 % from baseline.). The superiority of agomelatine over placebo was shown after two weeks of treatment.

Agomelatine did not differentiate from placebo in two trials (CL3-022, CAGO178A2303) where the active control fluoxetine or paroxetine showed assay sensitivity. In these trials agomelatine was not compared directly with paroxetine or fluoxetine as these comparators were included only to validate the assay sensitivity of the trials. In two other trials (CL3-023, 024), it was not possible to draw any conclusions because the active controls, paroxetine and fluoxetine, failed to differentiate from placebo.

Table 5 - Efficacy results in the pivotal short-term placebo-controlled trials agomelatine 25-50 mg

Trial (duration) Treatment group	HAM-D total score			HAM-D responder <sup>#</sup>	CGI <sup>###</sup> Severity		
	n	Baseline mean	Final mean	Final mean	n	Baseline mean	Final mean
<b>CL2-014 (8 weeks)</b>							
agomelatine 25mg	135	27.4	12.8 <sup>^</sup>	61.5% <sup>^</sup>	135	4.7	2.8 <sup>^</sup>
placebo	136	27.4	15.3	46.3%	136	5.0	3.3
paroxetine 20mg	144	27.3	13.1 <sup>^</sup>	56.3%	-	-	-
<b>CL3-042 (6 weeks)</b>							
agomelatine 25-50mg	116	27.4	13.9 <sup>^</sup>	54.3% <sup>^</sup>	116	4.9	3.1 <sup>^</sup>
placebo	119	27.2	17.0	35.3%	119	4.9	3.6
<b>CL3-043 (6 weeks)</b>							
agomelatine 25-50mg	106	26.5	14.1 <sup>^</sup>	49.1% <sup>^</sup>	106	4.8	3.2 <sup>^</sup>
placebo	105	26.7	16.5	34.3%	105	4.8	3.6
<b>CL3-069 (6 weeks)</b>							
agomelatine 25 mg	138	26.7	14.0 <sup>^</sup>	50.7 % <sup>^</sup>	138	4.7	3.1 <sup>^</sup>
agomelatine 25-50 mg	136	26.7	13.9 <sup>^</sup>	52.2 % <sup>^</sup>	136	4.6	3.1 <sup>^</sup>
placebo	141	26.6	18.7	24.8 %	141	4.6	3.7

*Notes:* <sup>#</sup> Percentage of patients with a decrease in baseline HAM-D total score  $\geq$  50%

<sup>###</sup> CGI: Clinical Global Impression

<sup>^</sup> Statistically significant difference from placebo.

The short-term efficacy of 25-50 mg/day of agomelatine was also demonstrated in trial CL3-046 which assessed the antidepressant efficacy of agomelatine as a secondary objective compared to sertraline (50-100 mg/day) over a double-blind treatment period of six weeks where male or female patients, aged 18-60 years fulfilling DSM-IV criteria for MDD, received agomelatine 25-50 mg/day or sertraline 50-100 mg/day (see Table 6).

Table 6 - Efficacy results in short-term trial CL3-046 versus sertraline

Trial (duration) Treatment group	HAM-D total score			HAM-D responder <sup>#</sup>	CGI-Severity		
	n	Baseline mean	Final mean	Final mean	n	Baseline mean	Final mean
<b>CL3-046 (6 weeks)</b>							
agomelatine 25-50mg	150	26.1	10.3 <sup>^</sup>	70.0%	150	4.7	2.5 <sup>^</sup>
sertraline 50-100mg	156	26.5	12.1	61.5%	157	4.7	2.8

*Notes:* <sup>#</sup> Percentage of patients with a decrease in baseline HAM-D total score  $\geq$  50%

<sup>^</sup> Statistically significant difference in favour of agomelatine

The short-term efficacy of agomelatine was also shown in trial CL3-045 which demonstrated the antidepressant efficacy of agomelatine vs fluoxetine after a double-blind treatment period of eight weeks where male or female patients, aged 18-65 years fulfilling DSM-IV criteria for MDD, received agomelatine 25-50 mg/day or fluoxetine 20-40 mg/day (see Table 7).

Table 7 - Primary efficacy criterion results in short-term trial CL3-045 versus fluoxetine

Trial (duration) Treatment group	HAM-D total score				Superiority test <sup>^^</sup>
	n	Baseline W0 mean	Final W8 mean	Difference W8-W0 E [95% CI]	p-value
agomelatine 25-50mg	247	28.5	11.1	1.49 <sup>^</sup>	0.024
fluoxetine 20-40mg	257	28.7	12.7	[0.20; 2.77]	

*Notes:* <sup>^</sup> Statistically significant difference in favour of agomelatine

<sup>^^</sup> a priori superiority test: two-sided p-value to be compared to 0.05 following a non-inferiority test centred on a non-inferiority margin of -1.5: one-sided p-value of <0.001 compared to 0.025

Superiority (CL3-045 and CL3-046) or non-inferiority (CL3-052, CL3-035, CL3-056 and CL3-063) with agomelatine has been shown in six short-term efficacy trials in heterogeneous populations of adult patients with depression compared to SSRI/SNRI (sertraline, escitalopram, fluoxetine or venlafaxine). The antidepressant effect was assessed with the HAMD-17 score either as the primary (two studies) or secondary endpoint (four studies).

#### Acute treatment of MDD in the elderly

A double-blind, placebo-controlled eight week trial of agomelatine 25-50 mg/day in male and female patients with MDD aged ≥ 65 years (N=222, of which 151 were treated with agomelatine) demonstrated a statistically significant difference of 2.67 points on HAM-D total score, the primary outcome. Responder rate analysis favoured agomelatine. No improvement was observed in very elderly patients (≥ 75 years, N=69, of which 48 were treated with agomelatine), and agomelatine should not be used in that group.

#### Prevention of Relapse of Depression

The primary objective of trial CL3-041 was to assess the efficacy of agomelatine at flexible dose in the prevention of depressive relapse compared to placebo. In this trial, 492 patients received open label treatment with agomelatine 25 mg/day for eight to ten weeks, with an increase to 50 mg/day in patients who were not sufficiently improved after two weeks. Thereafter, the patients who responded to therapy (HAM-D total score ≤ 10) were randomised to receive treatment with agomelatine or placebo until relapse occurred for up to 44 weeks. 338 patients participated in the double blind, long-term portion of the trial: 165 were treated with agomelatine and 174 were treated with placebo. The primary efficacy criterion was the relapse, defined as HAM-D 17-item total score ≥ 16, or any withdrawal for lack of efficacy during the 44-week double-blind period.

The risk over time of relapse was significantly reduced by 54.2 % in the agomelatine group compared to the placebo group in trial CL3-041 (see Figure 1). As is indicated in Table 8, the percentage of patients with a relapse during the 24-week double-blind period was more than two times lower in the agomelatine group than in the placebo group.

Figure 1 - Time to relapse over the 24-week double blind trial period




Table 8 - Time to relapse analysis over 24 weeks

Group	No. of patients	Relapses		Cumulative incidence of relapse at 175 days E [95%CI]	Cox model HR E [95%CI]	Logrank p-value
		N	%			
Agomelatine 25-50mg	165	34	20.6	21.7 [15.19; 28.10]	0.458 [0.305; 0.690]	<0.0001
Placebo	174	72	41.4	46.6 [36.84; 56.41]		


Results over the 44-week double-blind treatment period confirm the efficacy of agomelatine 25-50 mg to prevent depressive relapse in patients with MDD and showed the maintenance of long-term efficacy. The percentage of patients with a relapse over the whole 44-week double-blind period remained more than two times lower in the agomelatine group than in the placebo group (see Table 9).

Table 9 - Time to relapse analysis over 44 weeks

Group	No. of patients	Relapses		Cumulative incidence of relapse at 308 days E [95%CI]	Cox model HR E [95%CI]	Logrank p-value
		N	%			
Agomelatine 25-50mg	165	39	23.6	23.9 [17.16; 30.70]	0.437 [0.298; 0.640]	<0.0001
Placebo	174	83	47.7	50.0 [42.20; 57.75]		

As shown in Figure 2, the risk over time of relapse was significantly reduced by more than half, 56.3 % in the agomelatine group compared to the placebo group.

Figure 2 - Time to relapse over the 44-week double blind trial period



In another relapse-prevention trial (CL3-021), agomelatine did not separate from placebo as a result of an unexplained low relapse rate in the placebo group (23.5%) compared to the agomelatine group (25.9%) which was unexpected and markedly lower than the mean placebo relapse rate reported in the literature.

Acute Treatment of Generalised Anxiety Disorder (GAD)

The efficacy and safety of agomelatine (25 mg & 50 mg/day) in generalised anxiety disorder have been studied in a clinical programme including more than 1,100 patients with GAD treated with agomelatine. On the primary endpoint of (HAM-A) total score in all three placebo-controlled short-term trials (12-week treatment) agomelatine demonstrated a statistically significant superiority compared to placebo. In addition, response and remission rates were superior with agomelatine vs placebo (see Table 10). Assay sensitivity was shown in the trial including escitalopram as a validator.

Table 10 - HAM-A total score (expressed as change from baseline) and response rates to treatment for the last value over 12 weeks for study

	Difference placebo – Agomelatine or Escitalopram				
	N	E	SE	95% CI	p-value
<b>CL2-040</b>					
<b>HAM-A total score (mean±SD)</b>					
Placebo	-13.2 ± 9.5	58			
Agomelatine	-16.6 ± 8.9	63	3.28	1.58	[0.15;6.41] 0.040 <sup>1</sup>
<b>HAM-A response rate (%)</b>					
Placebo	46.6	58			
Agomelatine	66.7	63	-20.11	8.84	[-37.44; -2.79] 0.026 <sup>2</sup>
<b>CL3-071</b>					
<b>HAM-A total score (mean±SD)</b>					
Placebo	-10.6 ± 9.5	131			
Agomelatine 25-50mg	-15.6 ± 9.4	139	4.71	1.03	[2.69;6.73] <0.0001 <sup>3</sup>
Escitalopram 10-20mg	-15.6 ± 8.2	139	4.77	1.03	[2.74;6.79] <0.0001 <sup>3</sup>
<b>HAM-A response rate (%)</b>					
Placebo	36.6	131			
Agomelatine 25-50mg	64.0	139	-27.39	5.86	[-38.86;-15.91] <0.0001 <sup>2</sup>
Escitalopram 10-20mg	66.2	139	-29.55	5.82	[-40.94;-18.15] <0.0001 <sup>2</sup>
<b>CL3-087</b>					
<b>HAM-A total score (mean±SD)</b>					
Placebo	-6.9 ± 9.2	140			
Agomelatine 10mg	-13.7 ± 8.7	130	7.16	1.00	[5.19;9.13] <0.0001 <sup>3</sup>
Agomelatine 25mg	-18.0 ± 7.7	138	11.08	0.98	[9.14;13.01] <0.0001 <sup>3</sup>
<b>HAM-A response rate (%)</b>					
Placebo	22.86	140			
Agomelatine 10mg	51.54	130	-28.68	5.64	[-39.74; -17.63] <0.0001 <sup>2</sup>
Agomelatine 25mg	70.29	138	-47.43	5.27	[-57.75; -37.11] <0.0001 <sup>2</sup>

**Notes:** SD: Standard Deviation; E: estimate of the difference between treatment groups; SE: Standard Error  
 1: general linear model with baseline as covariate, previous psychotropic treatment intake as fixed effect, centre as random effect  
 2: Chi-Square test  
 3: Covariance analysis with adjustment for baseline and centre as random effect

The results for meta-analyses performed on the change from baseline to W12 in HAM-A total score (primary criterion) and response to treatment at W12 in the pool of studies summarising the efficacy of agomelatine versus placebo are detailed in Table 11.

**Table 11 - HAM-A total score - Change from baseline to W12 and responder rates at W12 - meta-analysis of short-term placebo-controlled studies (CL2-040, CL3-071 and CL3-087)**

	Agomelatine 25 & 25-50 mg (N = 340)	Placebo (N = 329)
<b>HAM-A total score (mean ± SD)</b>		
Baseline	28.8 ± 3.9	28.5 ± 3.6
Change to W12 (LOCF)	-16.8 ± 8.7	-9.5 ± 9.6
<i>Diff. from placebo (change to W12 LOCF)</i>		
E (SE) <sup>(1)</sup>	6.43 (2.50)	
95% CI <sup>(2)</sup>	[1.53; 11.32]	
p-value <sup>(3)</sup>	0.010	
<b>HAM-A Responders (%)*</b>		
% at W12 (LOCF)	67.06	32.52

Diff. from placebo (at W12 LOCF)

E (SE) <sup>(1)</sup>	32.55 (8.40)
95% CI <sup>(2)</sup>	[16.09; 49.02]
p-value <sup>(3)</sup>	< 0.001

**Notes:** N: Number of patients with value; SD: Standard Deviation; E: estimate of the difference between treatment groups; SE: Standard Error; LOCF: Last observation carried forward

Meta-Analysis: Overall Treatment Effect Using A Random Effect Model

(1) Overall estimate (standard error) of the difference between treatments:

Weighted mean of effects of treatment (adjusted on baseline and centre for the HAM-A total score [primary criterion]) estimated in the studies (Placebo minus Agomelatine 25 & 25-50 mg for score) (respectively Agomelatine 25 & 25-50 mg minus Placebo for responders). A positive estimate indicates greater improvement in Agomelatine 25 & 25-50 mg as compared to Placebo.

(2) 95% Confidence interval of the estimate

(3) Overall treatment effect: Meta-analytic methods

\*A responder to treatment was defined as a patient with a decrease in baseline HAM-A total score > 50%

Efficacy was also observed in more severely anxious patients in the three placebo-controlled trials. The meta-analyses of HAM-A total score in GAD patients in the three short-term placebo-controlled studies (CL2-040, CL3-071, CL3-087) showed a significant treatment effect of agomelatine 25 and 25-50 mg in severely ill patients (defined successively by a HAM-A total score  $\geq$  25 at baseline or, a HAM-A total score  $\geq$  25 and CGI-S  $\geq$  5 at baseline) (See Table 12).

Table 12 - HAM-A total score - Change from baseline to W12 (LOCF) in more severe patients - Meta-analysis of placebo-controlled studies (CL2-040, CL3-071 and CL3-087) - W0-W12 period

Subsets of the FAS Treatment group	N	E (SE) <sup>(1)</sup>	Difference vs placebo (change from baseline to W12 LOCF)	
			95% CI <sup>(2)</sup>	p-value <sup>(3)</sup>
<b>All</b>				
Agomelatine 25 & 25-50 mg	340	6.43 (2.50)	[1.53; 11.32]	0.010
Placebo	329			
<b>HAM-A &gt; 25</b>				
Agomelatine 25 & 25-50 mg	296	6.69 (2.76)	[1.28; 12.11]	0.015
Placebo	291			
<b>HAM-A &gt; 25 &amp; CGI-S &gt; 5</b>				
Agomelatine 25 & 25-50 mg	193	7.69 (2.84)	[2.13; 13.26]	0.007
Placebo	172			

**Notes:** N: Number of patients with value; SD: Standard Deviation; E: estimate of the difference between treatment groups; SE: Standard Error; LOCF: Last observation carried forward; FAS: Full Analysis Set

Meta-Analysis: Overall Treatment Effect Using A Random Effect Model

(1) Overall estimate (standard error) of the difference between treatments:

Weighted mean of effects of treatment (adjusted on baseline and centre) estimated in the studies (Placebo minus Agomelatine 25 & 25-50 mg). A positive estimate indicates greater improvement in Agomelatine 25 & 25-50 mg as compared to Placebo

(2) 95% Confidence interval of the estimate

(3) Overall treatment effect: Meta-analytic methods

Prevention of Relapse of GAD


The maintenance of efficacy in generalised anxiety disorder was demonstrated in a relapse prevention trial [CL3-050]. The primary efficacy criterion was relapse during the double-blind treatment period defined as a HAM-A total score  $\geq 15$ , or a lack of efficacy as judged by the clinician among patients who responded to the open-label treatment. Patients responding to 16-weeks of acute treatment with open-label agomelatine 25 mg once daily, with a possible up titration to 50 mg once daily after four weeks, were randomised to either agomelatine 25-50 mg or placebo for further six months (26 weeks). Agomelatine 25-50 mg once daily demonstrated a statistically significant superiority compared to placebo ( $p=0.046$ ) on the primary outcome measure, the prevention of anxious relapse, as measured by time to relapse. The incidence of relapse during the 6-month double-blind follow up period was 19.5 % and 30.7 % [95% CI: 0.641;0.995) for agomelatine and placebo, respectively. In patients treated with agomelatine, the risk of relapse over time was significantly reduced by 41.8% compared to placebo ( $p = 0.045$ ) (see Table 13).

Table 13 - Number of patients with relapse during the 26-week double-blind period, incidence over time and risk of relapse over 26 weeks

Group	No. of patients	Relapses <sup>1</sup>		Logrank p-value <sup>2</sup>	Incidence of relapse at	Logrank p-value <sup>2</sup>
		N	%		182 days E [95% CI]	
Agomelatine 25-50mg	113	22	19.5	0.046	0.582 <sup>3</sup>	0.045
Placebo	114	35	30.7		[0.341; 0.995] <sup>4</sup>	

- Notes:
- 1: Total number and percentage of patients having a relapse during the double-blind period
  - 2: Stratified or adjusted for country
  - 3: Estimate (Standard Error) of the Hazard Ratio (adjusted) of relapse between treatment groups: agomelatine vs placebo.
  - 4: 95% confidence interval of the estimate.

Figure 3 – Time to anxious relapses over 26 weeks survival curves (CL3-050)



Discontinuation symptoms in study CL3-050 were assessed by the Discontinuation Emergent Signs and Symptoms (DESS) checklist in patients having completed the study up to week 42 and re-randomised either on placebo or agomelatine. Absence of discontinuation syndrome after abrupt agomelatine treatment cessation was confirmed in this population.

Switching to agomelatine from other antidepressants (SSRIs or SNRIs)

A specific controlled, three-week trial (CL3-073) was conducted in 316 patients with MDD who had experienced insufficient improvement with paroxetine (an SSRI) or venlafaxine (an SNRI). When treatment was switched from these antidepressants to agomelatine, discontinuation symptoms arose after cessation of the SSRI or SNRI treatment, either after abrupt cessation or gradual cessation of the previous treatment. These discontinuation symptoms may be confounded with a lack of early benefit of agomelatine. The percentage of patients with at least one discontinuation symptom one week after the SSRI/SNRI treatment was stopped was lower in the long tapering group (gradual cessation of the previous SSRI/SNRI within two weeks) than in the short tapering group (gradual cessation of the previous SSRI/SNRI within one week) and in the abrupt substitution group (abrupt cessation): 56.1 %, 62.6 % and 79.8 % respectively.

## **5.2 PHARMACOKINETIC PROPERTIES**

### **Absorption**

Agomelatine is rapidly and well absorbed ( $\geq 80\%$ ) after oral administration. The peak plasma concentration is reached within one to two hours after administration of agomelatine. Absolute bioavailability is low (approximately 1 % at the therapeutic oral dose) and is highly variable due to the first pass effect and the inter-individual differences of CYP1A2 activity. The bioavailability is increased in women compared to men. Although not clinically relevant, the bioavailability is increased by intake of oral contraceptives and reduced by smoking. In the therapeutic dose-range, agomelatine exposure appears to increase proportionally with dose with saturation of the first pass effect occurring at supra-therapeutic doses (from 200 to 1200 mg).

Food intake (standard meal or high fat meal) reduced the peak concentration ( $C_{max}$ ) by approximately 20 - 30 % but did not modify overall absorption or bioavailability. The variability is increased with high fat food.

### **Distribution**

Steady state volume of distribution is about 35 L. Plasma protein binding is 95 % irrespective of concentration and is not modified with age and in patients with renal impairment but the free fraction is doubled in patients with hepatic impairment.

### **Metabolism**

Following oral administration, agomelatine is rapidly oxidized mainly by the hepatic cytochromes CYP1A2 (90 %) and CYP2C9/CYP2C19 (10 %). The major metabolites, hydroxylated and demethylated agomelatine, are not pharmacologically active and are rapidly conjugated and eliminated in the urine.

### **Excretion**

Elimination is rapid. The mean plasma half-life is between one and two hours. Clearance is high (about 1100 mL/min) and essentially metabolic. Excretion is mainly urinary (80 %) and corresponds to metabolites. Urinary excretion of the unchanged compound is negligible. Pharmacokinetics remained unchanged following repeated administration.

### **Special Populations**

#### Severe renal impairment

In subjects with severe renal impairment the pharmacokinetic parameters  $C_{max}$  and AUC were slightly higher than in healthy subjects. However, due to the high inter-individual variability of agomelatine

pharmacokinetics, this result was not clinically relevant. Renal impairment did not affect the protein binding of agomelatine.

### Hepatic Impairment

Following a single oral dose of 25 mg agomelatine in patients with hepatic impairment,  $C_{max}$  increased by a factor of ~60 and ~110, while AUC increased by ~70-times and ~140-times, in mild (Child-Pugh score of 5 or 6) and moderate (Child-Pugh score of 7 to 9) hepatic impairment, respectively compared to healthy subjects. Both mild and moderate liver impairment increased the half-life of agomelatine by a factor of ~3. The unbound fraction of agomelatine was also increased in subjects with hepatic insufficiency. The inter-individual variability decreased with mild hepatic impairment, with a further decrease in moderate hepatic impairment, suggesting a progressive saturation of the hepatic first-pass effect. Agomelatine is therefore contraindicated in patients with hepatic impairment (see *section 4.3 - Contraindications*).

### Gender, smoking and age

No significant difference in exposure was shown between the young and the elderly as well as between males and females. Although not clinically relevant:

- a 3.7-fold decrease in mean exposure was observed in volunteers without depression who were heavy smokers ( $\geq 15$  cigarettes per day)
- a decrease of 33 % of agomelatine exposure has been shown in the smoker population (healthy volunteers and patients with depression smoking  $> 5$  cigarettes per day) compared to non-smoker population, suggesting that cigarette smoking could induce CYP1A2 which is involved in the metabolism of agomelatine
- in a pharmacokinetic study in elderly patients (aged  $\geq 65$  years), mean AUC and mean  $C_{max}$  were about 4-fold and 13-fold respectively higher for very elderly patients aged  $\geq 75$  years compared to elderly patients aged  $< 75$  years, after an agomelatine dose of 25 mg. The results of that study were derived from a population pharmacokinetic analysis using data from saliva samples. No plasma samples were used in the study to determine or confirm correlation with the saliva samples. The total number of patients receiving agomelatine 50 mg was too low to draw any conclusions. No dose adaptation is recommended in elderly patients solely because of their age (up to the age of 75 years). Agomelatine should not be used in patients aged 75 years and older.

## 5.3 PRECLINICAL SAFETY DATA

### **Genotoxicity**

Based on results from a standard battery of *in vitro* and *in vivo* assays, agomelatine is not considered to have genotoxic potential in humans receiving the maximum proposed clinical dose.

### **Carcinogenicity**

Oral lifetime carcinogenicity trials with agomelatine were conducted in mice and rats. Male and female mice showed increased incidences of hepatocellular adenomas and hepatocellular carcinomas at systemic exposures (plasma AUC) about 15-fold human exposure at the maximal recommended clinical dose; the no-effect exposure was about 4-fold clinical exposure. Male rats showed an increased incidence of hepatocellular carcinomas at systemic exposures (plasma AUC) about 45-fold human exposure at the maximal recommended clinical dose; the no-effect exposure was about 8-fold clinical exposure. These effects were associated with liver enzyme induction in these species and are unlikely to be relevant to humans. In male and female rats, the frequency of benign mammary fibroadenomas was increased at high

systemic exposures (30-fold or greater the exposure at the maximal recommended clinical dose) but remained within the historical control range. Malignant mammary tumours were not observed.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 LIST OF EXCIPIENTS

- Lactose monohydrate
- Maize starch
- Povidone
- Sodium starch glycolate type A
- Stearic acid
- Magnesium stearate
- Colloidal anhydrous silica
- Hypromellose
- Yellow iron oxide
- Glycerol
- Macrogol 6000
- Titanium dioxide
- TekPrint SB-6003 Blue Ink containing: shellac, propylene glycol and indigo carmine aluminium lake.

### 6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

### 6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

### 6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store in a dry place below 30 °C.

### 6.5 NATURE AND CONTENTS OF CONTAINER

Supplied in PVC/Al blister packs of 7, 28 and 56 tablets<sup>1</sup>.

### 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

### 6.7 PHYSICOCHEMICAL PROPERTIES


The active component of DOMION is agomelatine which has the chemical name:  
N-[2-(7-methoxy-1-naphthyl)ethyl] acetamide and molecular formula: C<sub>15</sub>H<sub>17</sub>NO<sub>2</sub> (MW = 243.3).  
Agomelatine is practically insoluble in purified water (< 0.1 mg/mL) but freely soluble (> 100 mg/mL) in

---

<sup>1</sup> The 7 tablet and 56 tablet packs are not currently supplied in Australia

various organic solvents (96% ethanol, methanol, methylene chloride). Agomelatine has no asymmetric carbon atom.

### **Chemical structure**



### **CAS number**

138112-76-2

## **7 MEDICINE SCHEDULE (POISONS STANDARD)**

S4 - Prescription only medicine

## **8 SPONSOR**

Servier Laboratories (Aust.) Pty. Ltd.

[www.servier.com.au](http://www.servier.com.au)

Building 9, Level 4

588A Swan Street

Burnley, 3121, Victoria

## **9 DATE OF FIRST APPROVAL**

15 November 2016

## **10 DATE OF REVISION**

16 May 2022

### **SUMMARY TABLE OF CHANGES**

<b>Section(s) Changed</b>	<b>Summary of new information</b>
4.1, 4.2, 4.4, 4.5, 4.8, 5.1	New indication – GAD; periodic review